Characteristics of 1202 study participants
| Patient characteristics . | Number (%) . |
|---|---|
| Sex | |
| Male | 715 (59%) |
| Female | 487 (41%) |
| Age, y | |
| 0-1 | 267 (22%) |
| 2-5 | 266 (22%) |
| 6-9 | 193 (16%) |
| 10-15 | 181 (15%) |
| ≥ 16 | 295 (25%) |
| (mean = 12.3 and median = 7.2, range = 1 mo-67 y) | |
| Ethnic background (unknown = 18) | |
| Asian | 49 (4%) |
| African | 228 (19%) |
| Hispanic | 211 (18%) |
| Native American | 10 (1%) |
| Middle Eastern | 21 (2%) |
| White | 660 (56%) |
| Other | 5 (0.4%) |
| Diagnosis | |
| Leukemia | 771 (64%) |
| ALL | 353 (29%) |
| AML | 301 (25%) |
| CML | 81 (7%) |
| Other | 36 (3%) |
| Myelodysplasia | 58 (5%) |
| Lymphoma | 38 (3%) |
| Genetic | 294 (24%) |
| Metabolic | 92 (8%) |
| Immune deficiency | 86 (7%) |
| Bone marrow failure | 69 (6%) |
| Histiocytosis | 30 (2%) |
| Red blood cell disease | 16 (1%) |
| Platelet disease | 1 (0.1%) |
| Severe aplastic anemia | 32 (3%) |
| Other | 9 (1%) |
| Stage of ALL, AML, CML (unknown = 31, including 10 known not to be advanced by IBMTR criteria) | |
| Early | 163 (23%) |
| Intermediate | 327 (46%) |
| Advanced | 214 (30%) |
| Prior transplant (unknown = 70) | |
| None | 1031 (91%) |
| Allogeneic | 52 (5%) |
| Autologous | 46 (4%) |
| Unknown type | 3 (0.3%) |
| Preparatory regimen (unknown = 131) | |
| Myeloablative | 987 (92%) |
| Nonmyeloablative | 84 (8%) |
| GVHD prophylaxis (unknown = 219) | |
| Cyclosporine and Steroids | 610 (62%) |
| Any methotrexate | 167 (17%) |
| Tacrolimus (without methotrexate) | 112 (11%) |
| Other (without methotrexate) | 94 (10%) |
| Center experience | |
| < 50 NYBC CBUs | 665 (55%) |
| ≥ 50 NYBC CBUs | 537 (45%) |
| Year of transplant | |
| 1993-1996 | 224 (19%) |
| 1997-1999 | 459 (38%) |
| 2000-2002 | 238 (20%) |
| 2003-2006 | 281 (23%) |
| HLA mismatch (HLA-A, -B, -DRB1) | |
| 0 mismatches | 72 (6%) |
| 1 bidirectional mismatch | 364 (30%) |
| 2 bidirectional mismatches | 526 (44%) |
| GVHD only | 58 (5%) |
| Rejection only | 40 (3%) |
| 2 MM, bidirectional + GVHD | 83 (7%) |
| 2 MM, bidirectional + rejection | 54 (4%) |
| 2 MM, GVHD + rejection | 5 (0.4%) |
| NIMA match | |
| 0 mismatches | 72 (6%) |
| NIMA match | 82 (7%) |
| No NIMA match | 1005 (84%) |
| Unknown | 43 (4%) |
| Total nucleated cell dose (x 107/kg) | |
| 0.7-2.4 | 255 (21%) |
| 2.5-4.9 | 407 (34%) |
| 5.0-9.9 | 306 (25%) |
| ≥ 10.0 | 234 (19%) |
| Geometric mean = 4.9 × 107/kg, median = 4.5 × 107/kg, range = 0.7-70.9 | |
| Patient characteristics . | Number (%) . |
|---|---|
| Sex | |
| Male | 715 (59%) |
| Female | 487 (41%) |
| Age, y | |
| 0-1 | 267 (22%) |
| 2-5 | 266 (22%) |
| 6-9 | 193 (16%) |
| 10-15 | 181 (15%) |
| ≥ 16 | 295 (25%) |
| (mean = 12.3 and median = 7.2, range = 1 mo-67 y) | |
| Ethnic background (unknown = 18) | |
| Asian | 49 (4%) |
| African | 228 (19%) |
| Hispanic | 211 (18%) |
| Native American | 10 (1%) |
| Middle Eastern | 21 (2%) |
| White | 660 (56%) |
| Other | 5 (0.4%) |
| Diagnosis | |
| Leukemia | 771 (64%) |
| ALL | 353 (29%) |
| AML | 301 (25%) |
| CML | 81 (7%) |
| Other | 36 (3%) |
| Myelodysplasia | 58 (5%) |
| Lymphoma | 38 (3%) |
| Genetic | 294 (24%) |
| Metabolic | 92 (8%) |
| Immune deficiency | 86 (7%) |
| Bone marrow failure | 69 (6%) |
| Histiocytosis | 30 (2%) |
| Red blood cell disease | 16 (1%) |
| Platelet disease | 1 (0.1%) |
| Severe aplastic anemia | 32 (3%) |
| Other | 9 (1%) |
| Stage of ALL, AML, CML (unknown = 31, including 10 known not to be advanced by IBMTR criteria) | |
| Early | 163 (23%) |
| Intermediate | 327 (46%) |
| Advanced | 214 (30%) |
| Prior transplant (unknown = 70) | |
| None | 1031 (91%) |
| Allogeneic | 52 (5%) |
| Autologous | 46 (4%) |
| Unknown type | 3 (0.3%) |
| Preparatory regimen (unknown = 131) | |
| Myeloablative | 987 (92%) |
| Nonmyeloablative | 84 (8%) |
| GVHD prophylaxis (unknown = 219) | |
| Cyclosporine and Steroids | 610 (62%) |
| Any methotrexate | 167 (17%) |
| Tacrolimus (without methotrexate) | 112 (11%) |
| Other (without methotrexate) | 94 (10%) |
| Center experience | |
| < 50 NYBC CBUs | 665 (55%) |
| ≥ 50 NYBC CBUs | 537 (45%) |
| Year of transplant | |
| 1993-1996 | 224 (19%) |
| 1997-1999 | 459 (38%) |
| 2000-2002 | 238 (20%) |
| 2003-2006 | 281 (23%) |
| HLA mismatch (HLA-A, -B, -DRB1) | |
| 0 mismatches | 72 (6%) |
| 1 bidirectional mismatch | 364 (30%) |
| 2 bidirectional mismatches | 526 (44%) |
| GVHD only | 58 (5%) |
| Rejection only | 40 (3%) |
| 2 MM, bidirectional + GVHD | 83 (7%) |
| 2 MM, bidirectional + rejection | 54 (4%) |
| 2 MM, GVHD + rejection | 5 (0.4%) |
| NIMA match | |
| 0 mismatches | 72 (6%) |
| NIMA match | 82 (7%) |
| No NIMA match | 1005 (84%) |
| Unknown | 43 (4%) |
| Total nucleated cell dose (x 107/kg) | |
| 0.7-2.4 | 255 (21%) |
| 2.5-4.9 | 407 (34%) |
| 5.0-9.9 | 306 (25%) |
| ≥ 10.0 | 234 (19%) |
| Geometric mean = 4.9 × 107/kg, median = 4.5 × 107/kg, range = 0.7-70.9 | |
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; GVH, graft-versus-host; GVHD, graft-versus-host disease; IBMTR, International Blood and Marrow Transplant Registry; MM, mismatch; NIMA, noninherited maternal antigen; and NYBC, New York Blood Center.